CNR1 and chronic myelogenous leukemia, BCR-ABL1 positive: Gholizadeh et al found that administering CB1/CB2 agonists to K562 chronic myelogenous leukemia cells decreased MMP9 and MMP2 whereas administration of a CB1 antagonist led to the opposite effect.48